ReviewEuropean journal of cancer (Oxford, England : 1990)2010
The KISS1 metastasis suppressor: a good night kiss for disseminated cancer cells.
Review in European journal of cancer (Oxford, England : 1990), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 82 citations in OpenAlex.
- Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men.British journal of clinical pharmacology · 2013Trial
- Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications.Journal of the Endocrine Society · 2026Review
- Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.Advances in therapy · 2025Article
- Association between KISS1 gene and growth traits in two Middle Eastern sheep breeds: the Iranian Karakul and the Iraqi Awassi.Tropical animal health and production · 2025Article
- Evidence for KISS-1 nuclear translocation and PI3K/AKT signaling in the ultrastructurally and morphometrically analyzed human endometriosis.Frontiers in cell and developmental biology · 2025Article
- SCAP contributes to embryonic angiogenesis by negatively regulating KISS-1 expression in mice.Cell death & disease · 2023Article
- Recapitulating thyroid cancer histotypes through engineering embryonic stem cells.Nature communications · 2023Article
- KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?Cancer metastasis reviews · 2023Review
- Insights of Endocytosis Signaling in Health and Disease.International journal of molecular sciences · 2023Review
- Molecular interaction of metastasis suppressor genes and tumor microenvironment in breast cancer.Exploration of targeted anti-tumor therapy · 2023Review
- Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.BMC cancer · 2022Article
- Endocytosis: a pivotal pathway for regulating metastasis.British journal of cancer · 2021Review
- Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications.Endocrine · 2020Review
- KISS1 in metastatic cancer research and treatment: potential and paradoxes.Cancer metastasis reviews · 2020Review
- Role of the tumor microenvironment in regulating the anti-metastatic effect of KISS1.Clinical & experimental metastasis · 2020Review
- KISS1 in breast cancer progression and autophagy.Cancer metastasis reviews · 2019Review
- Minireview: The Epigenetic Modulation ofInternational journal of environmental research and public health · 2019Review
- Automated quantitative image analysis for ex vivo metastasis assays reveals differing lung composition requirements for metastasis suppression by KISS1.Clinical & experimental metastasis · 2018Article
- Controversial Role of Kisspeptins/KiSS-1R Signaling System in Tumor Development.Frontiers in endocrinology · 2018Review
- Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives.Frontiers in endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Re-expression of KISS1 in tumor cell lines allows all antecedent steps of metastasis, but prevents colonization of secondary sites. Because tumor cells have already disseminated by the time of cancer diagnosis, KISS1 may represent a new opportunity for therapeutic intervention. Moreover, numerous clinical reports demonstrate that a loss or reduction of KISS1 expression in different human cancers inversely correlates with tumor progression, metastasis, and survival. Taken together, these observations compel the hypothesis that KISS1 could be of tremendous utility in controlling metastasis in a therapeutic context. In this review, we highlight some key findings from preclinical and clinical studies and discuss strategies whereby KISS1 may be exploited clinically to treat metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.